Hepatitis C News and Research

Latest Hepatitis C News and Research

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Janssen-Cilag International NV today announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products.

16 May 2014

Chronic bystander viral impairs development of memory T cells

Studies of vaccine programs in the developing world have revealed that individuals with chronic infections such as malaria and hepatitis tend to be less likely to develop the fullest possible immunity benefits from vaccines for unrelated illnesses.

16 May 2014

First Edition: May 16, 2014

Today's headlines include reports about the Indiana governor's alternative plan to expand Medicaid. Kaiser Health News staff writer Sarah Varney, working in collaboration with PBS Newshour, reports: "Men and women involved in the criminal justice system are more likely to be sicker than the general population, with higher rates of diabetes, hypertension, depression, mood disorders and alcohol and drug addiction.

16 May 2014

U.S. urges daily pill for those at risk of AIDS

The recommendation could transform AIDS prevention from reliance on condoms to a regimen that relies on an antiretroviral drug. Meanwhile, a report analyzes the costs and benefits of treating prison inmates for hepatitis C and a study finds that nearly half of American adults take prescriptions.

16 May 2014

Isis Pharmaceuticals receives $3 million milestone payment from GSK

Isis Pharmaceuticals, Inc. announced today that it has earned a $3.0 million milestone payment from GlaxoSmithKline (GSK) related to the initiation of a natural history study, which will support the advancement of one of the alliance programs.

15 May 2014

Medicare roundup: Alabama pain clinic spending 'hotspot'; quality improvement program scrutinized

Also, the controversy about paying for a hepatitis-C cure and reinstating physicians who lost their licenses.

13 May 2014

Spring Bank announces 3 presentations on SB 9200 at 27th ICAR

Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel drugs to treat a number of medical conditions, with a primary focus in antivirals, today announced three presentations on SB 9200, its lead drug candidate for the treatment of Hepatitis B (HBV) and Hepatitis C (HCV) infections, at the 27th International Conference on Antiviral Research (ICAR) being held May 12-16, 2014 at the Raleigh Convention Center in Raleigh, NC.

12 May 2014

First Edition: May 12, 2014

Today's headlines include news about the inner-workings of some state-based health exchanges. Reporting for Kaiser Health News, in collaboration with NPR, Richard Knox writes: "Previous drug treatments didn't clear the virus from Bianco's system. But it's almost certain that potent new drugs for hep-C could cure him.

12 May 2014

Inovio Pharmaceuticals reports total revenue of $2.4 million for first quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2014.

12 May 2014

Scientists decrypt interaction network of hepatitis C virus proteins in living human cells

Scientists at the Helmholtz Zentrum München have for the first time decrypted the interaction network of hepatitis C virus proteins in living human cells. Their findings will contribute to a better understanding of the mechanisms behind inflammatory liver disease caused by hepatitis C viruses and open up new avenues for therapy development.

9 May 2014

AbbVie seeks marketing approval from EMA for all-oral, interferon-free therapy to treat HCV infection

AbbVie submitted marketing authorization applications (MAAs) to the European Medicines Agency seeking approval for the company’s investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection.

9 May 2014

Recycling patients' red blood cells during heart surgery better than banked blood transfusion

Patients whose own red blood cells are recycled and given back to them during heart surgery have healthier blood cells better able to carry oxygen where it is most needed compared to those who get transfusions of blood stored in a blood bank, according to results of a small study at Johns Hopkins.

9 May 2014

Luminescent nanocrystals tags with high-speed scanning technology detects multiple viruses within minutes

A research team using tunable luminescent nanocrystals as tags to advance medical and security imaging have successfully applied them to high-speed scanning technology and detected multiple viruses within minutes.

9 May 2014

Emergent BioSolutions reports total revenue of $53.9 million for Q1 2014

Emergent BioSolutions Inc. reported total revenue for Q1 2014 of $53.9 million as compared to $43.1 million in 2013. In addition, Q1 2014 net loss was $20.2 million, or $0.55 per share, as compared to a net loss of $8.1 million, or $0.22 per share, in 2013.

9 May 2014

Hepatocellular carcinoma on the rise among Mexican Americans

Hepatocellular carcinoma (HCC), the primary cancer of the liver, is on the verge of becoming an epidemic among Mexican Americans, especially in Texas.

8 May 2014

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO™ in the United States, in combination with the nucleotide analog NS5B polymerase inhibitor sofosbuvir developed by Gilead Sciences, Inc.

8 May 2014

Hepatitis C News and Research

Latest Hepatitis C News and Research

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Chronic bystander viral impairs development of memory T cells

First Edition: May 16, 2014

U.S. urges daily pill for those at risk of AIDS

Isis Pharmaceuticals receives $3 million milestone payment from GSK

Medicare roundup: Alabama pain clinic spending 'hotspot'; quality improvement program scrutinized

Spring Bank announces 3 presentations on SB 9200 at 27th ICAR

First Edition: May 12, 2014

Inovio Pharmaceuticals reports total revenue of $2.4 million for first quarter 2014

Scientists decrypt interaction network of hepatitis C virus proteins in living human cells

AbbVie seeks marketing approval from EMA for all-oral, interferon-free therapy to treat HCV infection

Recycling patients' red blood cells during heart surgery better than banked blood transfusion

Luminescent nanocrystals tags with high-speed scanning technology detects multiple viruses within minutes

Emergent BioSolutions reports total revenue of $53.9 million for Q1 2014

Hepatocellular carcinoma on the rise among Mexican Americans

Janssen submits sNDA to FDA for simeprevir in combination with sofosbuvir for treatment of HCV genotype 1 infection

Janssen expands collaboration with IPM for development of dapivirine to prevent HIV

State highlights: SEIU, hospital strike deal in Calif.; N.Y. Medicaid audit; dental therapists

MinuteClinic walk-in medical clinics open in central Georgia

Humana reports EPS of $2.35 in Q1 2014; confirms EPS guidance for FY14

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Hepatitis C News and Research

Latest Hepatitis C News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in